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Methods that used specimens from three genital sites (penile brushing [PB], urethral brushing [UB], and
the retrieval of semen [SE]) from 50 men were examined for human papillomavirus (HPV) DNA detection. The
rates of detection by PB, UB, SE, PB and UB, and PB and SE were 88.9%, 50.0%, 33.3%, 100%, and 97.2%,
respectively. The use of PB and UB appears to be the most accurate method; as an alternative to UB, the use
of SE with PB could be used to improve the rate of HPV DNA detection in men.
Infection with high-risk human papillomavirus (HPV) is the
main cause of cervical cancer (7). Since men have been sug-
gested to play a likely role as reservoirs and vectors for HPV
infection (8, 12, 28), screening of men may be relevant for the
prevention of cervical cancer in women.
In the absence of clinical lesions, the most reliable diagnostic
strategy for men is testing for HPV DNA (25). As recently
reviewed (10), HPV infection rates in males range from 1.0%
to 82.9%. In addition to the different profiles of the patients
and the different HPV assays used, this wide range of rates may
also be due to the variation in the clinical material analyzed
(e.g., penile surface, preputial cavity, glans, scrotum, urethra,
semen, and urine) because of a lack of agreement on the
anatomical sites that should be sampled. Of the few studies
that compared different specimens from men (1, 2, 11, 22),
some reported that penile brushing (PB) represents the most
sensitive method, while others selected urethral brushing (UB)
or the retrieval of semen (SE). To assess the most adequate
procedure, useful information could be obtained by comparing
different samples from “high-risk” men, such as the sexual
partners of HPV-positive women (8, 16, 25). To this aim, this
study researched specimens from different sites for HPV DNA
by three different methods, namely, PB, UB, and SE. The
specimens were from 50 partners (age range, 23 to 58 years;
mean age, 36.7 years) of HPV-positive women consecutively
referred between May 2003 and May 2005 to the Department
of Hygiene and Microbiology, University of Palermo, Palermo,
Italy. The study was approved by the university ethical com-
mittee.
Patients were instructed not to wash their genitalia on the
day before the examination and to have 2 days of sexual ab-
stinence. Three types of genital specimens were collected in
parallel. The first type was collected by PB, which consisted of
the collection of cells from the dorsal and the ventral surfaces
of the penile shaft, sampled with a standard-sized, dry cotton-
tipped swab, and cells from the inner part of the foreskin,
coronal sulcus, frenulum, and glans, sampled with a saline-
prewetted cytobrush. Five to six backward and forward swab or
brush movements were performed at each site, and all these
samples were placed in the same tube containing 3 ml of
phosphate-buffered saline (PBS). The second sample was ob-
tained by UB, for which a very thin, saline-prewetted brush was
inserted 1.5 cm into the urethra, rotated 360 degrees, and
removed; when it was required by the patients, a 2% lidocaine
gel was applied before sampling by UB. The cells obtained by
UB were also placed in 3 ml of PBS. The third sample was
obtained by SE, with the semen collected by masturbation and
placed in sterile containers. If the sample was obtained at
home, the sample was transferred to the laboratory within 2 h
after ejaculation. All of the samples obtained by PB, UB, and
SE were immediately processed for DNA extraction. Cells
obtained by PB and UB were spun down at 13,000 rpm for 5
min, resuspended in 200 to 500 l of 1 M Tris-HCl (pH 8.3)–
0.45% Tween 20, 0.45% Nonidet P-40 containing 200 g/ml
proteinase K, and incubated at 60°C for 2 h and 95°C for 10
min. The samples obtained by SE were maintained at room
temperature until complete liquefaction (if the sample was
very viscous, it was maintained at 37°C for 10 to 15 min).
Samples obtained by SE were processed with a commercial
NucleoSpin Tissue mini column (Macherey-Nagel, Düren,
Germany), and two 50-l aliquots of the samples obtained by
SE were analyzed. Samples obtained by SE were initially di-
gested at 56°C for 15 min in the T1 buffer supplied with the kit,
sperm cells were removed by centrifugation at 1,600 rpm for 10
min, and the supernatant was extracted by following the man-
ufacturer’s protocol. A final volume of 100 l was obtained; the
SE sample fraction analyzed was primarily composed of epi-
thelial cells. Amplifications were carried out in a Mastercycler
(Eppendorf, Germany) and the products of all PCR assays
were analyzed in 8% polyacrylamide gel, as described else-
where (14). Clinical samples were checked for DNA quality
and the absence of inhibitors of amplification by analysis for
the human -globin gene (14); only -globin-positive samples
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were examined for HPV DNA. The INNO-LiPA HPV geno-
typing system (version 1) kit (Innogenetics N.V., Ghent, Bel-
gium) was used for HPV DNA amplification and genotyping by
following the manufacturer’s protocol. Briefly, 5 l of each
sample was amplified with biotinylated SPF10 primers, which
amplify a 65-bp fragment of the L1 open reading frame and
allow detection of at least 43 different HPV types (20). There-
after, the amplicons were hybridized with 24 oligonucleotide
probes, specific for 15 high-risk types (HPV types 16, 18, 31, 33,
35, 39, 45, 51, 52, 53, 56, 58, 59, 66, and 68) and 9 low-risk types
(HPV types 6, 11, 40, 42, 43, 44, 54, 70, and 74). Due to the
higher numbers of genotypes detected by the SPF10 primers
(43 HPV types) than by the specific probes (24 HPV types),
some samples yielded SPF10-positive, hybridization-negative
results. These HPV types not identifiable with the INNO-LiPA
system were subsequently amplified by a nested PCR assay
with the outer primer pair MY09-MY11 and the inner primer
pair GP05-GP06, and genotyping was performed by direct
cycle sequencing analysis, as described elsewhere (14, 15). A
total of 10 l of the extracted sample and controls was mixed
with PCR buffer (50 mM KCl, 10 mM Tris-HCl [pH 8.4], 1.5
mM MgCl2), 200 M of each deoxynucleoside triphosphate, 50
pmol of the MY09-MY11 primer pair, and 1 U of AmpliTaq
Gold polymerase (Perkin-Elmer Cetus, Berkeley, CA) in a
final volume of 50 l. Following Taq polymerase activation and
template denaturation for 8 min at 95°C, the procedure in-
cluded 4 cycles of 30 s at 95°C, 2 min at 60°C, and 45 s at 72°C
(step 1) and then 6 cycles of 30 s at 95°C, 2 min at 57°C, and
45 s at 72°C (step 2) and 40 cycles of 30 s at 95°C, 30 s at 53°C,
and 45 s at 72°C (step 3). The last cycle was extended by a
4-min elongation step at 72°C. In the second round of the
amplification, 2 l of the first PCR product was amplified with
30 pmol of the GP5-GP6 primer pair in the same reaction
mixture described above, except that the concentration of
MgCl2 was 2 mM. After a first step of 10 min at 95°C, a total
of 35 cycles of 30 s at 95°C, 30 s at 45°C, and 45 s at 72°C were
performed, followed by a final 5-min extension step at 72°C.
For the sequencing analysis, amplification products were puri-
fied by the use of Microcon YM-100 filter devices (Amicon;
Millipore); when secondary amplification products were
present, the PCR product was electrophoresed through 1%
agarose and the band of interest was extracted with Ultra-
free-DA filter devices (Amicon; Millipore). About 5 ng of the
purified nested PCR product was added to 4 l of the BigDye
Terminator ready reaction mix (Perkin-Elmer Applied Biosys-
tems), 4 l of 0.8 M primer, and deionized water to a final
volume of 20 l. The cycle incubator program consisted of 25
cycles of 30 s at 96°C, 45 s at 45°C, and 1 min at 60°C. Purifi-
cation of the reaction mixtures and removal of free BigDye
were performed with Centrisep spin columns (Princeton Sep-
arations, Adelphia, NJ). The reaction product was analyzed on
an ABI Prism 310 analyzer (Perkin-Elmer Applied Biosys-
tems). Alignments were obtained by use of the BLAST server
(http://www.ncbi.nlm.nih.gov). HPV genotypes were consid-
ered low or high risk according to a recently published classi-
fication of HPV types (9).
Data were analyzed by using the SAS (Institute Cartz, NC)
package and the 2 test (significance was a P value 0.05); in
case of a significant 2 test result, the Student range Q of
Tukey was used to assess any significant difference among
groups (13).
Warts were observed in three (8.3%) cases. Positive results
for -globin were obtained in 47 (94.0%) samples obtained by
PB, 48 (96.0%) samples obtained by UB, and 45 (90.0%)
samples obtained by SE (P  0.05). Among the adequate
samples, HPV was found in 32/47 (68.0%) samples obtained by
PB, 18/48 (37.5%) samples obtained by UB, and 12/45 (26.6%)
samples obtained by SE, for a total of 36/50 (72.0%) positive
men (Table 1). Among the HPV-positive men, the HPV de-
tection rate by PB was 32/36 (88.9%), that by UB was 18/36
(50%; Q  8.6; P  0.01), and that by SE was 12/36 (33.3%;
Q  7.3; P  0.01). The detection rate by PB and UB com-
bined was 36/36 (100%), and that by PB and SE combined was
35/36 (97.2%; P  0.05). Of 32 samples obtained by PB, 6
(18.7%) harbored low-risk types (Table 2), 11 (34.3%) har-
bored high-risk types, and 15 (46.8%) harbored mixed types
(P  0.05); of 18 samples obtained by UB, the rates were 5
(27.7%) for low-risk types, 7 (38.8%) for high-risk types, and 6
(33.3%) for mixed types (P  0.05); and of 12 samples ob-
tained by SE, the rates were 3 (25.0%) for low-risk types, 5
(41.6%) for high-risk types, and 4 (33.3%) for mixed types
(P  0.05). Fourteen patients with adequate DNA at all sites
had HPV infection at more than one site: for only nine
(64.3%) of the patients the samples obtained by PB con-
tained (all) the HPV type(s) infecting the patient, while for
the remaining cases the samples obtained by UB and/or SE
harbored types in addition to or different from those found
in the samples obtained by PB. A total of 16 high-risk
genotypes and 11 low-risk genotypes were detected, of
which the most prevalent were HPV type 31 (HPV-31)
(19.4%), HPV-53 (16.6%), HPV-6 (13.8%), and HPV-16
(11.1%). Mixed infections were found in 20 (57.1%) men.
In this analysis, sampling by PB, UB, and SE yielded satis-
factory amplification results (a 90% rate of successful -glo-
bin detection). The method used for sampling by PB is a
critical issue, since some procedures may yield inadequate
samples at a high frequency (5, 6, 17, 19). Of note, the method
used in this analysis was also rated as easy to tolerate by all the
men. For sampling by UB, some studies reported the detection
of -globin in only 13% and 65% of cases (2, 6); since the
collection methods used in this study and in the previously
reported studies were similar, inadequate results may be due to
the laboratory techniques used for DNA analysis. Surprisingly,
TABLE 1. HPV DNA results by genital site for 50 men
No. of
men
Genital site examined by:
PB UB SE
6   
5   
3   
3   NDa
3 ND  
11   
1   
2  ND 
2   ND
14   
a ND, not determined due to a negative -globin result.
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the use of controls for inhibitory material in semen before
HPV testing was reported by only a few authors (2, 18, 26, 27).
Because of the large quantity of PCR inhibitors present in
semen (23, 24), testing for -globin is strongly suggested to
avoid the risk of false-negative HPV results.
HPV was found in 72.0% of the partners of HPV-positive
women, in line with the findings of previous reports (16, 25). Of
note, only 8.3% of the men had genital warts, confirming that
mostly subclinical infections are found in men (6). Sampling by
PB yielded the highest HPV rate (68.0%), followed by sam-
pling by UB (37.5%) and SE (26.6%). Thus, sampling by PB,
which is the only sampling method used in many studies, is
confirmed to be the most adequate. In contrast, sampling by
UB resulted in a low detection rate, as has also been found in
other studies (4, 10), in which the rate of HPV DNA detection
by UB ranged from 21% to 37%. Similarly, testing of semen for
HPV was not efficacious, with only a 26.6% detection rate,
which falls in the range of 23.4% to 39.0% reported in the
literature (3, 18, 21). Even though sampling by UB and SE was
less adequate than sampling by UB alone, when associated
with the latter method, UB and SE each still contributed to
HPV DNA detection; thus, the results from this study would
result in the recommendation for parallel testing by PB plus
UB or SE, which yielded 100% and 97.2% rates of HPV DNA
detection, respectively. This finding is consistent with that of
Nicolau et al. (25), who found that the HPV detection rate
increased from 58.0% to 70.0% when the UB method was
added to the PB method.
No difference in the prevalence of a specific genotype or
group of HPV was found by PB, UB, and SE. For UB, this
finding is in contrast to that of a study with a similar male
population (4), in which infection of the urethra was mostly
caused by low-risk HPV types. Among males infected at mul-
tiple sites, in only 64.3% of the cases the type detected by PB
was representative of the type(s) infecting the patient. This
finding is in contrast to those of Aynaud et al., who found the
same type in penile/urethral biopsy specimens as in the spec-
imens obtained by SE and UB (3, 4), suggesting possible con-
tamination. In this analysis, the presence of a different type(s)
in samples obtained by UB and SE than in samples obtained by
PB suggested actual multifocal infection involving either the
urethra or distant parts of the reproductive tract (21, 29). A
high prevalence of mixed HPV infections (up to 57.1%) was
found in the study group. Although the clinical significance of
infection with multiple HPV types in men has still not been
determined, a role in the acquisition or persistence of infection
has been suggested (19).
In conclusion, data from the present analysis seem to indi-
cate PB combined with UB is the best sampling method for the
testing of men for HPV; as an alternative to UB, sampling by
PB and SE combined could be applied to improve the rate of
detection of HPV DNA in men.
The work for this study was performed at Dipartimento di Igiene e
Microbiologia, Università di Palermo, Palermo, Italy.
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